The Prognostic Significance of Tumoral Melanosis
- PMID: 39357874
- DOI: 10.1111/cup.14727
The Prognostic Significance of Tumoral Melanosis
Abstract
Background: Tumoral melanosis (TM) is a histological term to describe a nodular aggregation of macrophages containing melanin pigment (melanophages) that is devoid of viable melanocytes. It is most often identified in skin, where it may be appreciated clinically as a pigmented lesion; however, it can also be found in other organs such as lymph nodes. The presence of TM is usually thought to signify the presence of a regressed melanoma or other pigmented tumor. Until recently, it was a relatively uncommon finding; however, with the use of effective systemic therapies against melanoma, its occurrence in histological specimens is more frequent.
Methods: We identified and reviewed all histopathological diagnoses of TM at any organ site reported at a single institution from 2006 to 2018. TM cases were paired with non-TM cases of cutaneous melanoma through propensity score matching at a 1:2 ratio, and their survival outcomes were compared. The clinical outcomes examined included recurrence-free survival (RFS), distant disease-free survival (DDFS), melanoma-specific survival (MSS), and overall survival (OS).
Results: TM was reported in 79 patients. Their median age was 65 years (range 22-88), with a 2:1 male predominance (51 out of 79, 65%). The most common organ involved was the skin (67%), with a third of all cases localized to a lower limb (36%). TM had a strong association with the presence of melanoma (91%) and regression at other sites of melanoma (54%), suggesting that it is part of a systemic immune response against melanoma. Most patients with TM either previously or subsequently developed histologically confirmed melanoma in the same anatomical region as the TM (89%). Thirty-five TM patients were matched with 70 non-TM cases. Patients with melanoma who developed TM without prior regional or systemic therapy showed improved MSS (p = 0.03), whereas no statistically significant differences were observed in terms of RFS, DDFS, and OS.
Conclusions: TM usually occurs in the context of a previous or subsequent cutaneous melanoma and is associated with improved MSS. It is important that TM is recognized by pathologists and documented in pathology reports.
Keywords: immunotherapy; melanoma; melanophages; melanosis; pathology; pigmentation; prognosis; regression; treatment; tumoral.
© 2024 The Author(s). Journal of Cutaneous Pathology published by John Wiley & Sons Ltd.
References
-
- I. Satzger, B. Volker, A. Kapp, and R. Gutzmer, “Tumoral Melanosis Involving the Sentinel Lymph Nodes: A Case Report,” Journal of Cutaneous Pathology 34 (2007): 284–286.
-
- S. Dogruk Kacar, P. Ozuguz, S. Karaca, and F. Aktepe, “Tumoral Melanosis in an Adolescent After Trauma: A Clinicopathological Dilemma,” Pediatric Dermatology 31 (2014): e69–e70.
-
- I. Kieran, D. Mowatt, K. Gajanan, P. Shenjere, and D. Kosutic, “Tumoral Melanosis Nine Years After Wide Local Excision of a Thin Melanoma,” Dermatologic Surgery 42 (2016): 779–780.
-
- R. L. Grohs and A. N. Mesbah, “Melanoma Manifesting as Tumoral Melanosis; Now You See It, Now You Don't,” American Journal of Dermatopathology 40 (2018): 462–465.
-
- N. Yang, M. Ruan, and S. Jin, “Melanosis Coli: A Comprehensive Review,” Gastroenterología y Hepatología 43 (2020): 266–272.
Grants and funding
LinkOut - more resources
Full Text Sources
